PROFILE OF CD150 EXPRESSION IN BONE MARROW CELLS OF PATIENTS WITH ACUTE MYELOID LEUKEMIA
DOI:
https://doi.org/10.32471/exp-oncology.2312-8852.vol-44-no-3.18307Keywords:
acute myeloid leukemia., bone marrow cells, CD150, immunophenotypeAbstract
Background: Acute myeloid leukemia (AML) is a highly heterogeneous disease accompanied by the arrest of myeloid cell lineage differentiation due to accumulation of genetic abnormalities and clonal proliferation of myeloid blasts. Finding the differentially expressed molecules and studying their function within AML subgroups may help to improve diagnosis and prognosis with the aim of developing selected therapies for AML subsets. The aim of this study was to reveal the profile of CD150 cell surface expression on bone marrow (BM) cells of AML patients. Materials and Methods: The study was performed on samples of BM aspirates from 55 patients with primarily diagnosed AML. Flow cytometry analysis was applied for the evaluation of immunophenotype profile and CD150 cell surface expression on BM cells from AML patients. Results: Four AML subtypes (M1, M2, M3 and M5) were identified. The CD150 expression was found in 14 (25.5%) cases predominantly of AML M3 subtype. CD150 expression was detected on 43.2–83.8% of leukemia cells in AML M3. The frequency of CD150 positive cases of non-M3 AML subtypes was low: all AML M1 cases were CD150-negative, while only 1 (10.0%) of 10 patients with AML M2 and 6 (19.4%) of 31 patients with AML M5 were CD150 positive. The median percentage of CD150 positive leukemia cells and the index of mean fluorescence intensity in AML M3 cases were significantly higher than in non-M3 AML cases (p < 0.05). The CD150 expression was significantly associated with CD11c, CD11b, CD14, CD34, CD36, CD56 and HLA-DR negative expression and CD33, CD38, CD117 positive expression among the examined cohort of patients with AML M3. Conclusions: High level of CD150 expression is a unique feature of AML M3 subtype and may serve as additional phenotype marker for the identification of blast cells with impaired maturation at the promyelocyte stage and the development of AML M3. At the same time, the revealed negative association of CD150 expression with poor prognostic factor CD56 in AML M3 subtype also allows us to suggest potential prognostic value of CD150 examination in AML patients.
References
Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ 2021; 375: n2026. https://doi.org/10.1136/bmj.n2026
Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451–8. https://doi.org/10.1111/j.1365-2141.1976.tb03563.x
Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985; 103: 620–5. https://doi.org/10.7326/0003-4819-103-4-620
Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016; 127: 2391–405. https://doi.org/10.1182/blood- 2016-03-643544
Sidorenko SP, Clark EA. Characterization of a cell surface glycoprotein IPO-3, expressed on activated human B and T lymphocytes. J Immunol 1993; 151: 4614–24.
Gordiienko I, Shlapatska L, Kovalevska L, et al. SLAMF1/CD150 in hematologic malignancies: Silent marker or active player? Clin Immunol 2019; 204: 14–22. https://doi.org/10.1016/j.clim.2018.10.015
Wood BL, Arroz M, Barnett JM, et al. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom 2007; 72: 14–22. https://doi.org/10.1002/cyto.b.20363
van Dongen JJ, Orfao A. EuroFlow: Resetting leukemia and lymphoma immunophenotyping. Basis for companion diagnostics and personalized medicine. Leukemia 2012; 26: 1899–907. https://doi.org/10.1038/leu.2012.121
Syampurnawati M, Tatsumi E, Furuta K, et al. HLA-DR-negative AML (M1 and M2): FLT3 mutations (ITD and D835) and cell-surface antigen expression. Leuk Res 2007; 31: 921–9. https://doi.org/10.1016/j.leukres.2007.11.017
Kussick SJ, Yi HS, Sheets KM, et al. A distinctive nuclear morphology in acute myeloid leukemia is strongly associated with loss of HLA-DR expression and FLT3 internal tandem duplication. Leukemia 2004; 18: 1591–8. https://doi.org/10.1038/sj.leu.2403458
Devi K, Ali N. The curious case of HLA-DR-positive APL. Clin Case Rep 2021; 9: 825–9. https://doi.org/10.1002/ccr3.3683
Dong HY, Kung JX, Bhardwaj V, et al. Flow cytometry rapidly identifies all acute promyelocytic leukemias with high specificity independent of underlying cytogenetic abnormalities. Am J Clin Pathol 2011; 135: 76–84. https://doi.org/10.1309/AJCPW9TSLQNCZAVT
Noguera NI, Catalano G, Banella C, et al. Acute promyelocytic leukemia: update on the mechanisms of leukemogenesis, resistance and on innovative treatment strategies. Cancers (Basel) 2019; 11: 1591. https://doi.org/10.3390/cancers11101591
Moon H, Lee S, Huh J, et al. Characteristics of acute myeloid leukemia without HLA-DR expression. Korean J Lab Med 2007; 27: 313–7. https://doi.org/10.3343/kjlm.2007.27.5.313
El-Meligui YM, Abd Elrhman HE, Salahuddin A, et al. Correlation study on HLA-DR and CD117 (c-kit) expressions: its prognosis and treatment response in acute myeloid leukemia patients. Pharmgenomics Pers Med 2021; 14: 381–93. https://doi.org/10.2147/PGPM.S268986
Oelschlaegel U, Mohr B, Schaich M, et al. HLA-DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia. Cytometry B Clin Cytom 2009; 76: 321–7. https://doi.org/10.1002/cyto.b.20475
Paietta E. Expression of cell-surface antigens in acute promyelocytic leukemia. Best Pract Res Clin Haematol 2003; 16: 369–85. https://doi.org/10.1016/s1521-6926(03)00042-2
Kaleem Z, Crawford E, Pathan H, et al. Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data. Arch Pathol Lab Med 2003; 127: 42–8. https://doi.org/10.5858/2003-127-42-FCAOA
Gorczyca W. Acute promyelocytic leukemia: four distinct patterns by flow cytometry immunophenotyping. Pol J Pathol 2012; 63: 8–17.
Gluzman DF, Sklyarenko LM, Telegeev GD, et al. Diagnosis of myeloid neoplasms and acute leukemias. Scientific and methodical guide. Kyiv: DIA, 2016. 124 p. (in Ukrainian)
Rastogi P, Sachdeva MU. Flow cytometric minimal residual disease analysis in acute leukemia: current status. Indian J Hematol Blood Transfus 2020; 36: 3–15. https://doi.org/10.1007/s12288-019-01118-5
Bain BJ, Béné MC. Morphological and immunophenotypic clues to the WHO categories of acute myeloid leukaemia. Acta Haematol 2019; 141: 232–44. https://doi.org/10.1159/000496097
Stubbins RJ, Karsan A. Differentiation therapy for myeloid malignancies: beyond cytotoxicity. Blood Cancer J 2021; 11: 193. https://doi.org/10.1038/s41408-021-00584-3
Aanei CM, Veyrat-Masson R, Rigollet L, et al. Advanced flow cytometry analysis algorithms for optimizing the detection of “different from normal” immunophenotypes in acute myeloid blasts. Front Cell Dev Biol 2021; 9: 735518. https://doi.org/10.3389/fcell.2021.735518
Thalhammer-Scherrer R, Mitterbauer G, Simonitsch I, et al. The immunophenotype of 325 adult acute leukemias: relationship to morphologic and molecular classification and proposal for a minimal screening program highly predictive for lineage discrimination. Am J Clin Pathol 2002; 117: 380–9. https://doi.org/10.1309/C38D-D8J3-JU3E-V6EE
Klobusicka M, Kusenda J, Babusikova O. Myeloid enzymes profile related to the immunophenotypic characteristics of blast cells from patients with acute myeloid leukemia (AML) at diagnosis. Neoplasma 2005; 52: 211–8.
Hamed EO, El-Deen AF. Flow cytometric diagnosis of acute leukemia and aberrant antigen: sohag university experience. Open J Blood Diseases 2018; 8: 37-48. https://doi.org/10.4236/ojbd.2018.82005
Al-Mawali A, To LB, Gillis D, et al. The presence of leukaemia-associated phenotypes is an independent predictor of induction failure in acute myeloid leukaemia. Int J Lab Hematol 2009; 31: 61–8. https://doi.org/10.1111/j.1751-553X.2007.01003.x
Pinchouk VG, Sidorenko SP, Gluzman DF, et al. Monoclonal antibodies IPO-3 and IPO-10 against human B-cell differentiation antigens. Anticancer Res 1988; 8: 1377–80.
De Salort J, Sintes J, Llinàs L, et al. Expression of SLAM (CD150) cell-surface receptors on human B-cell subsets: from pro-B to plasma cells. Immunol Lett 2011; 134: 129–36. https://doi.org/10.1016/j.imlet.2010.09.021
Romero X, Benitez D, March S, et al. Differential expression of SAP and EAT-2-binding leukocyte cell-surface molecules CD84, CD150 (SLAM), CD229 (Ly9) and CD244 (2B4). Tissue antigens 2004; 64: 132–44. https://doi.org/10.1111/j.1399-0039.2004.00247.x
Laksono BM, Grosserichter-Wagener C, de Vries RD, et al. In vitro measles virus infection of human lymphocyte subsets demonstrates high susceptibility and permissiveness of both naive and memory B-cells. J Virol 2018; 92: e00131–18. https://doi.org/10.1128/JVI.00131-18
Gordiienko IM, Shlapatska LM, Kovalevska LM, et al. Differential expression of CD150/SLAMF1 in normal and malignant B-cells on the different stages of maturation. Exp Oncol 2016; 38: 101–7.
Yurchenko M, Skjesol A, Ryan L, et al. SLAMF1 is required for TLR4-mediated TRAM-TRIF-dependent signaling in human macrophages. J Cell Biol 2018; 217: 1411–29. https://doi.org/10.1083/jcb.201707027
Basso G, Buldini B, de Zen L, et al. New methodologic approaches for immunophenotyping acute leukemias. Haematologica 2001; 86: 675–92.
Wetzler M, McElwain BK, Stewart CC, et al. HLA-DR antigen-negative acute myeloid leukemia. Leukemia 2003; 17: 707–15.
Syampurnawati M, Tatsumi E, Ardianto B, et al. DR negativity is a distinctive feature of M1/M2 AML cases with NPM1 mutation. Leuk Res 2008; 32: 1141–3. https://doi.org/10.1016/j.leukres.2007.11.017
Gupta A, Mishra D, Chandy M, et al. Human leucocytic antigen-DR negative acute myeloid leukemia: A diagnostic dilemma for hematopathologist. Clin Cancer Invest J 2014; 3: 383–7. https://doi.org/10.4103/2278-0513.138055
Horna P, Zhang L, Sotomayor EM, et al. Diagnostic immunophenotype of acute promyelocytic leukemia before and early during therapy with all-trans retinoic acid. Am J Clin Pathol 2014; 142: 546–52. https://doi.org/10.1309/AJCPPOKEHBP53ZHV
Liu M, Weng X, Gong S, et al. Flow cytometric analysis of CD64 expression pattern and density in the diagnosis of acute promyelocytic leukemia: a multi-center study in Shanghai, China. Oncotarget 2017; 8: 80625–37. https://doi.org/10.18632/oncotarget.20814
Mosleh M, Mehrpouri M, Ghaffari S, et al. Report of a new six-panel flow cytometry marker for early differential diagnosis of APL from HLA-DR negative non-APL leukemia. Scand J Clin Lab Invest 2020; 80: 87–92. https://doi.org/10.1080/00365513.2019.1700427
Siraj F, Tanwar P, Singh A, et al. Analysing “tear-drop” prints of acute promyelocytic leukemia (APML): immunophenotypic prognostication of APML by FCM. Am J Blood Res 2021; 11: 446–57.
Zhou Y, Jorgensen JL, Wang SA, et al. Usefulness of CD11a and CD18 in flow cytometric immunophenotypic analysis for diagnosis of acute promyelocytic leukemia. Am J Clin Pathol 2012; 138: 744–50. https://doi.org/10.1309/AJCPQU9R3FSLKFMI
Xu F, Yin CX, Wang CL, et al. Immunophenotypes and immune markers associated with acute promyelocytic leukemia prognosis. Dis Markers 2014; 2014: 421906. https://doi.org/10.1155/2014/421906
Pinheiro L, Trindade L, Costa A, et al. Aberrant phenotypes in acute myeloid leukemia and its relationship with prognosis and survival: A systematic review and meta-analysis. Int J Hematol Oncol Stem Cell Res 2020; 14: 274–88. https://doi.org/10.18502/ijhoscr.v14i4.4484
Promsuwicha O, Auewarakul CU. Positive and negative predictive values of HLA-DR and CD34 in the diagnosis of acute promyelocytic leukemia and other types of acute myeloid leukemia with recurrent chromosomal translocations. Asian Pac J Allergy Immunol 2009; 27: 209–16.
Вologna C, Buonincontri R, Serra S, et al. SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response. J Clin Invest 2016; 126: 181–94. https://doi.org/10.1172/JCI83013
Schweighofer CD, Coombes KR, Barron LL, et al. A two-gene signature, SKI and SLAMF1, predicts time-to-treatment in previously untreated patients with chronic lymphocytic leukemia. PLoS One 2011; 6: e28277. https://doi.org/10.1371/journal.pone.0028277
van Lochem EG, van der Velden VHJ, Wind HK, et al. Immunophenotypic differentiation patterns of normal hematopoiesis in human bone marrow: reference patterns for age-related changes and disease-induced shifts. Cytometry B Clin Cytom 2004; 60: 1–13. https://doi.org/10.1002/cyto.b.20008
Matarraz S, Almeida J, Flores-Montero J. Introduction to the diagnosis and classification of monocytic-lineage leukemias by flow cytometry. Cytometry B Clin Cytom 2017; 92: 218–27. https://doi.org/10.1002/cyto.b.21219
Zushi Y, Sasaki M, Mori A, et al. Acute monocytic leukemia diagnosed by flow cytometry includes acute myeloid leukemias with weakly or faintly positive non-specific esterase staining. Hematol Rep 2018; 10: 7435. https://doi.org/10.4081/hr.2018.7435
Ouyang G, Xu Z, Jiang D, et al. Clinically useful flow cytometry approach to identify immunophenotype in acute leukemia. J Int Med Res 2019; 47: 1483–92. https://doi.org/10.1177/0300060518819637
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Experimental Oncology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
